U.S. markets open in 2 hours 57 minutes

TherapeuticsMD, Inc. (TXMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.40+0.28 (+5.47%)
At close: 04:00PM EST
5.43 +0.03 (+0.56%)
Pre-Market: 04:05AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.12
Bid0.00 x 1300
Ask0.00 x 800
Day's Range4.60 - 5.45
52 Week Range1.99 - 30.50
Avg. Volume120,004
Market Cap51.122M
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-21.73
Earnings DateNov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TXMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TherapeuticsMD, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Business Wire

    TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

    BOCA RATON, Fla., December 04, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agree

  • Zacks

    TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates

    TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    TherapeuticsMD Announces Third Quarter 2022 Financial Results

    BOCA RATON, Fla., November 14, 2022--TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2022.